Company Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases.
Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.
The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease.
Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases.
The company was founded in 2013 and is headquartered in South San Francisco, California.
| Country | United States |
| IPO Date | Feb 7, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 241 |
| CEO | Dr. Arnon Rosenthal Ph.D. |
Contact Details
Address: 131 Oyster Point Boulevard South San Francisco, California United States | |
| Website | https://www.alector.com |
Stock Details
| Ticker Symbol | ALEC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001653087 |
| CUSIP Number | 014442107 |
| ISIN Number | US0144421072 |
| Employer ID | 82-2933343 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Arnon Rosenthal Ph.D. | Co-Founder, Chief Executive Officer & Director |
| Clare Hunt M.B.A. | Chief People Officer |
| Dr. Marc Grasso M.D. | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer |
| Danielle Pasqualone J.D., Ph.D. | General Counsel |
| Dr. Gary Romano M.D., Ph.D. | Chief Medical Officer |
| Dr. Saraswati Kenkare-Mitra Ph.D. | President and Head of Research & Development |
| Katie Hogan | Senior Director of Corporate Communication & Investor Relations |
| Kristina Cutter M.P.H. | Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer |
| Norah Conway | Senior Vice President of Portfolio & Program Management |
| Virginia DeJesus-Rueff M.B.A. | Chief of Staff & Head of Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 06, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Nov 25, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 06, 2024 | 10-Q | Quarterly Report |